Dx test maker Quidel grabs BioHelix for $10M-plus

The deal is done. Diagnostic test maker Quidel ($QDEL) now officially owns BioHelix, a Beverly, MA maker of nucleic acid technology for molecular diagnostic tests. Quidel is paying $10 million in cash up front, plus more money depending on a number of development and sales milestones. BioHelix was spun off from New England Biolabs in 2009, and has been collaborating with Quidel to develop hand-held disposable molecular assays. Quidel, based in San Diego, CA, recently won a CE mark for a new molecular diagnostic designed to screen for herpes and also a virus that causes chicken pox and shingles. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.